Abdominal Tumor, Aneurism, Cirrhosis, Intestinal Fistula, Intestinal Obstruction
Conditions
Brief summary
The alpha2 agonist dexmedetomidine is a new sedative agent combined with the analgesic qualities and lack of respiratory depression. Patients sedated with dexmedetomidine could be easily roused, these advances shows dexmedetomidine may be a effective and safe sedative agent. But some studies showed some adversely effects of dexmedetomidine on haemodynamics (such as bradycardia, hypotension), the investigators want to further research the effects of dexmedetomidine on haemodynamics, such as Cardiac Output (CO), Systemic Venous Resistance Index(SVRI), and so on. Propofol is widely used sedative agent in ICU, it also has adversely effects like bradycardia and hypotension, so the investigators want to compare the effect of dexmedetomidine with propofol on haemodynamics after major abdominal surgery. Expect to further research the mechanism of haemodynamics of dexmedetomidine.
Detailed description
When the patients can be roused, they will first receive analgesia with bolus of fentanyl 0.03mg, followed by a continuous infusion at a fixed dose of 0.3μg/kg/h during study period. Then patients will be randomly divided into two groups (Dexmedetomidine and Propofol). All of them will receive hemodynamic monitoring through Vigileo(Edwards Lifesciences) and cardiogram monitor. The study will continue for 6-24 hours.
Interventions
DRUGdexmedetomidine
dexmedetomidine: IV (in the vein)at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
DRUGpropofol
propofol: IV (in the vein)at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
Sponsors
First Affiliated Hospital, Sun Yat-Sen University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Postoperative patients of major abdominal surgery 2. Age ≧ 18
Exclusion criteria
1. heart rate ≤ 50 bpm 2. allergy with dexmedetomidine or propofol 3. pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac output | the study will start when the patient can be roused after major abdominal surgery and will continue for 6 to 24hours |
Secondary
| Measure | Time frame |
|---|---|
| Stroke Volume | the study will start when the patient can be roused after major abdominal surgery and will continue for 6 to 24hours |
Other
| Measure | Time frame |
|---|---|
| Systemic Venous Resistance Index | the study will start when the patient can be roused after major abdominal surgery and will continue for 6 to 24hours |
Countries
China
Contacts
Primary Contactmingyin chen, MD
Outcome results
None listed